CSIMarket
 


Neuropathix Inc.  (TYGS)
Other Ticker:  
 

Neuropathix's Quick Ratio

TYGS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Neuropathix's Cash & cash equivalent grew by 263.79 % in the I Quarter 2022 sequentially, faster than Current Liabilities, this led to improvement in Neuropathix's Quick Ratio to 0.03, Quick Ratio remained below Neuropathix Inc. average.

Within Major Pharmaceutical Preparations industry 605 other companies have achieved higher Quick Ratio than Neuropathix in first quarter 2022. While Quick Ratio total ranking in the first quarter 2022 has deteriorated compared to the prior quarter from 5155 to 5790.

Explain Quick Ratio?
How much Cash & cash equivalents TYGS“s has?
What are TYGS“s Current Liabilities?


TYGS Quick Ratio (Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
Y / Y Current Liabilities Change 47.4 % 17.18 % 26.63 % 15.15 % 53.7 %
Y / Y Cash & cash equivalent Change -64.94 % -15.89 % -28.02 % -58.83 % 158.39 %
Quick Ratio MRQ 0.03 0.01 0.01 0.03 0.14
TYGS's Total Ranking # 5790 # 5155 # 5319 # 2324 # 4891
Seq. Current Liabilities Change 20.63 % 12.6 % 5.29 % 3.06 % -4.1 %
Seq. Cash & cash equivalent Change 263.79 % 44.33 % -66.66 % -79.97 % 772.7 %



Quick Ratio first quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 606
Healthcare Sector # 1228
Overall Market # 5790


Quick Ratio Statistics
High Average Low
9.04 1.51 0
(Mar 31 2018)   (Jun 30 2017)




Financial Statements
Neuropathix's Current Liabilities $ 4 Millions Visit TYGS's Balance sheet
Neuropathix's Cash & cash equivalent $ 0 Millions Visit TYGS's Balance sheet
Source of TYGS's Sales Visit TYGS's Sales by Geography


Cumulative Neuropathix's Quick Ratio

TYGS's Quick Ratio for the trailling 12 Months

TYGS Quick Ratio

(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
Y / Y Current Liabilities TTM Growth 47.4 % 17.18 % 26.63 % 15.15 % 53.7 %
Y / Y Cash & cash equivalent TTM Growth -64.94 % -15.89 % -28.02 % -58.83 % 158.39 %
Quick Ratio TTM 0.02 0.04 0.05 0.05 0.06
Total Ranking TTM # 6029 # 4953 # 5463 # 5895 # 4079
Seq. Current Liabilities TTM Growth 20.63 % 12.6 % 5.29 % 3.06 % -4.1 %
Seq. Cash & cash equivalent TTM Growth 263.79 % 44.33 % -66.66 % -79.97 % 772.7 %


On the trailing twelve months basis Due to growth in Current Liabilities in the I Quarter 2022 to $3.60 millions, cumulative Quick Ratio decreased to 0.02 below the Neuropathix Inc. average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 615 other companies have achieved higher Quick Ratio than Neuropathix. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the forth quarter 2021 from 4953 to 6029.

Explain Quick Ratio?
How much Cash & cash equivalents TYGS“s has?
What are TYGS“s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 616
Healthcare Sector # 1251
Within the Market # 6029


trailing twelve months Quick Ratio Statistics
High Average Low
2.56 0.8 0.02
(Dec 31 2018)   (Mar 31 2022)




Companies with similar Quick Ratio in the quarter ending Mar 31 2022, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2022 MRQ Cash & cash equivalentMar 31 2022 MRQ Current Liabilities
International Stem Cell Corporation  0.08 $ 0.398  Millions$ 4.811  Millions
Viatris Inc   0.08 $ 752.400  Millions$ 9,642.900  Millions
Orgenesis Inc   0.07 $ 1.123  Millions$ 15.253  Millions
Sangui Biotech International Inc  0.07 $ 0.068  Millions$ 0.976  Millions
Northwest Biotherapeutics inc  0.05 $ 6.963  Millions$ 130.012  Millions
Cell Source Inc   0.05 $ 0.132  Millions$ 2.789  Millions
Innovation1 Biotech Inc   0.05 $ 1.370  Millions$ 29.276  Millions
Propanc Biopharma Inc   0.04 $ 0.134  Millions$ 3.117  Millions
Biostax Corp  0.04 $ 0.437  Millions$ 11.304  Millions
Bioadaptives Inc   0.04 $ 0.056  Millions$ 1.485  Millions
Apexigen Inc   0.04 $ 0.093  Millions$ 2.604  Millions
Neuropathix Inc.  0.03 $ 0.119  Millions$ 3.598  Millions
Integrated Biopharma Inc  0.03 $ 0.264  Millions$ 9.233  Millions
Emmaus Life Sciences Inc   0.02 $ 0.813  Millions$ 34.551  Millions
Kaya Holdings Inc  0.02 $ 0.203  Millions$ 8.769  Millions
Provectus Biopharmaceuticals Inc   0.02 $ 0.174  Millions$ 7.825  Millions
Cytodyn inc   0.02 $ 2.363  Millions$ 106.532  Millions
Statera Biopharma Inc fka Cytocom Inc   0.02 $ 0.331  Millions$ 15.073  Millions
Wellness Center Usa Inc  0.02 $ 0.064  Millions$ 2.959  Millions
Q Biomed inc   0.02 $ 0.137  Millions$ 6.368  Millions
Evofem Biosciences Inc   0.02 $ 2.761  Millions$ 154.474  Millions
Sunwin Stevia International Inc.  0.01 $ 0.321  Millions$ 22.005  Millions
Earth Science Tech Inc   0.01 $ 0.027  Millions$ 1.882  Millions
Novaccess Global Inc   0.01 $ 0.062  Millions$ 4.516  Millions
Actavia Life Sciences Inc   0.01 $ 0.028  Millions$ 2.174  Millions
Intellipharmaceutics International Inc   0.01 $ 0.084  Millions$ 7.222  Millions
Musclepharm Corporation  0.01 $ 0.534  Millions$ 48.171  Millions
Skinvisible Inc   0.01 $ 0.025  Millions$ 3.067  Millions

Date modified: 2022-05-24T19:24:55+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com